Date Re-Scheduled from March 11th
Martinsried/Munich (Germany) and Princeton, N.J., March 5, 2008 – GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced that the Company will hold a conference call on Thursday, March 27, 2008 to discuss financial results for the fiscal year 2007 and provide a company update. The financial results will be published on March 27th in advance of the call. The Company’s reporting date has been re-scheduled from March 11th to March 27th due to the extensive work required around the Company’s recent corporate restructuring activities.
Participants may listen via live webcast, accessible through the GPC Biotech Web site at www.gpc-biotech.com, or via telephone. A replay will be available on the Web site following the live event. The call, which will be conducted in English, will be held on March 27, 2008 at 14:00 CET/9:00 AM ET.
The dial-in numbers for the call are as follows:
Participants from Europe: 0049 (0)69 5007 1305 or
0044 (0)20 7806 1951
Participants from the U.S.: 1-718-354-1387
Please dial in 10 minutes before the beginning of the meeting.
About GPC Biotech
GPC Biotech AG is a publicly traded development-stage biopharmaceutical company focused on new anticancer drugs. GPC Biotech's lead product candidate is satraplatin, an oral platinum compound. The Company has various anti-cancer programs in research and development that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany) and has a wholly owned U.S. subsidiary in Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at www.gpc-biotech.com.
This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release We direct you to GPC Biotech’s Annual Report on Form 20-F for the fiscal year ended December 31, 2006 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of GPC Biotech. Forward-looking statements speak only as of the date on which they are made and GPC Biotech undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.
Contacts:
GPC Biotech AG
Martin Braendle
Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com
In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
usinvestors@gpc-biotech.com
